Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypertension, Heart Failure, and CKD Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AGT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AGT Recombinant Protein (Full-Length Precursor) & M235T Mutant High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View AGT Products |
| Gene Delivery | AGT Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. CMV promoter, Puro selection. |
View AGT Products |
| Benchmark Ab | Anti-AGT Recombinant Antibody (Clinical Benchmark Sequence) Recombinant positive control for assay development. |
View AGT Products |
| Validator | AGT siRNA Set (3 target-specific + 1 control) For knockdown verification in liver cell models. |
View AGT Products |
| Related Target: Renin | Renin (REN) Recombinant Protein Direct enzymatic partner; essential for AGT cleavage assays. |
View REN Products |
| Related Target: ACE | ACE Recombinant Protein Downstream effector for counter-screening and combination therapy studies. |
View ACE Products |
| Related Target: AGTR1 | AGTR1 (AT1 Receptor) Lentivirus Downstream GPCR mediating hypertensive effects; pathway validation and signaling studies. |
View AGTR1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-throughput Renin Cleavage Assays | High purity (>95%) AGT substrate, strictly Endotoxin Controlled, native glycosylation via HEK293. |
| In vitro RNAi / ASO Knockdown Validation | Validated siRNA sets included for baseline specificity and silencing checks. |
| Lack of Reliable Controls for PK/PD Assays | Sequence Verified recombinant benchmark antibodies for robust assay calibration. |
| Cross-species PK/PD & Toxicology (Human/Mouse/Cyno) | Human/Mouse/Cyno AGT ortholog proteins available; >95% purity; Sequence Verified for epitope mapping. |
| Serpin Subfamily Counter-screening | Homolog panel proteins (SerpinA1, SerpinA3) strictly verified by mass spec for mAb selectivity assays. |
| High-affinity binding validation (pM range required) | Tag-free AGT with native N-terminus; SPR/BLI validated theoretical binding sites. |
| Functional inhibition assay (Renin cleavage blockade) | Endotoxin-controlled (<1 EU/µg) active protein; Proteolytic stability verified. |
| False Positives | Validated siRNA included for specificity checks. |
Live AGT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AGT therapeutics is intensifying, with major players shifting focus from traditional downstream RAAS inhibitors (ACEi/ARBs) to upstream AGT targeting via RNA interference, antisense oligonucleotides, and monoclonal antibodies. As first-generation RNAi therapies (e.g., Zilebesiran by Alnylam/Roche) reach late-stage clinical trials, the next wave of R&D is targeting ultra-long-acting formulations (biannual dosing) and combination regimens for refractory hypertension, chronic kidney disease (CKD), and heart failure. Combination strategies with SGLT2 inhibitors and ARNIs are being explored to achieve comprehensive RAAS blockade without compensatory "renin escape".
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA | Alnylam, Roche | Hypertension, Heart Failure, CKD | Knockdown Validation (Need high-purity AGT protein for PK/PD correlation and validated siRNA sets) |
| ASO | Ionis Pharmaceuticals | Hypertension, CKD, Alport Syndrome | Silencing Specificity (Need Human/Mouse/Cyno AGT orthologs for cross-species screening) |
| Monoclonal Ab | Novartis, Takeda | Resistant Hypertension | Affinity maturation (Need SPR-grade AGT with native glycosylation) |
| Small Molecule / Peptide | Various Biotech | Essential Hypertension, Preeclampsia | Binding site characterization (Need fragment variants and high-purity AGT for enzymatic cleavage assays) |